| PharmaSUG CN |
2026 |
A Comprehensive R Shiny Application for Pharmacokinetic Analysis |
Keyi Zhang |
source |
17 |
| PharmaSUG CN |
2026 |
Modernizing the Vaccine TAUG: An End-to-End, Output-Driven Framework for Reactogenicity, Immunogenicity, Efficacy, and Reviewer-Ready Submissions |
Lin Chen, Jialiang Liu |
source |
18 |
| PharmaSUG |
2025 |
AI-Assisted Transition: from SAS to RStudio for PK Summary Analysis |
Shiqi Lin |
source |
9 |
| PharmaSUG |
2025 |
Programming Perspectives for Efficient and Accurate C-QTc Analysis |
Lingjie Zhang, Lata Maganti, Richard Moreton, Runcheng Li |
source |
11 |
| PHUSE EU |
2021 |
Preparing PK/PD ADaM Datasets and eCRT Data Package for FDA Submission |
Junying Zhang |
source video presentation source |
11 |
| PHUSE EU |
2021 |
Using Modular Programming to Create Mean Plots and Adverse Event Frequency Plots [presentation] |
Claus Stenberg |
source video |
28 |
| PHUSE EU |
2019 |
Bioequivalence Testing for Highly Variable Drug Products (HVDPs) |
James R. Johnson |
source presentation source |
9 |
| PharmaSUG |
2019 |
One Macro to Produce Descriptive Statistic Summary Tables with P-Values |
Rajaram Venkatesan, Harinarayanan Gopichandran |
source |
14 |
| WUSS |
2018 |
Better than Average: Calculating Geometric Means Using SAS |
Kim Roenfeldt |
source |
9 |
| MWSUG |
2017 |
AIR Binder 2.0: A Dynamic Visualization, Data Analysis and Reporting SAS Application for Preclinical and Clinical ADME Assays, Pharmacokinetics, Metabolite Profiling and Identification |
Hao Sun, Kristen Cardinal, Richard Voorman |
|
26 |
| SGF |
2017 |
Predictive Accuracy: A Misleading Performance Measure for Highly Imbalanced Data |
Josephine Akosa |
source |
12 |
| PharmaSUG |
2016 |
"I Want the Mean, But not That One!" |
David W. Franklin |
source |
5 |
| PharmaSUG |
2016 |
Programming Support for Exposure-Response Analysis in Oncology Drug Development |
Peter Lu, Hong Yan |
source |
8 |
| SESUG |
2015 |
Multifunctional SAS Macro for Fold Rise Calculation in Immunogenicity Analysis |
Yan Liu |
source |
4 |
| PharmaSUG |
2013 |
A Strategy to Ensure Non-Estimable Confidence Intervals Having Equal Lower and Upper Confidence Limits are Displayed Correctly |
Claudia Jimenez-Castro |
source |
5 |
| NESUG |
2012 |
Decision-Making Using the Analytic Hierarchy Process (AHP) and SAS/IML |
Melvin T. Alexander |
|
12 |
| PHUSE EU |
2012 |
Estimating Terminal Half Life by Non-Compartmental Methods with Some Data Below the Limit of Quantification |
Jochen Müller-Cohrs |
source |
6 |
| SESUG |
2012 |
Decision-Making Using the Analytic Hierarchy Process (AHP) and SAS/IML |
Melvin T. Alexander, Social Security |
source |
12 |
| NESUG |
2011 |
Geometric Statistics in PK Analysis - Programmeres Perspective |
Niraj J. Pandya, Smitha Mullapudi |
|
4 |
| PharmaSUG |
2010 |
Using SAS Proc Power to Perform Model-based Power Analysis for Clinical Pharmacology Studies |
Peng Sun |
|
11 |
| PharmaSUG |
2008 |
Statistical Approach to Establishing Bioequivalence |
William F. McCarthy, Nan Guo |
|
12 |
| PHUSE EU |
2007 |
Bootstrapping in a replicative bioequivalence study |
Feryal Tanriverdio, Arne Ring |
source |
11 |
| MWSUG |
1999 |
Sample Size Determination From A Pilot Bioequivalence Study For A Future Pivotal Bioequivalence Study: A SAS Procedure |
Xiang Gao, Henry Cheng |
|
7 |
| NESUG |
1996 |
BIOEQ4: Bioequivalence Macro to Create both Table and SAS data set according to the FDA Bioequivalence Guidelines Issued in 1992 |
Mary Kay McPherson |
|
6 |
| SESUG |
1994 |
MrPD - A SAS Software Application Using Desirability Functions For Optimization of Multiple Responses |
Walter T. Morgan |
|
6 |
| SUGI |
1994 |
MrPD - A SAS Software Application of Optimization of Multiple Responses Using Desirability Functions |
Walter T. Morgan, Ray W. Hawley |
source |
6 |
| SUGI |
1989 |
Computing the Standard Deviation from a Geometric Mean |
Daniel R. Bretheim |
source |
3 |
| SUGI |
1987 |
A Macro for Estimating the Box-Cox Power Transformation |
Andrew G. Stead |
source |
5 |
| SUGI |
1978 |
SAS and the Evaluation of Drug Reinforcement |
Philip I. Good, Michael S. Lajiness |
source |
6 |